{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:05Z","timestamp":1791668105212,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd001505.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000}}],"reference-count":57,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001505.pub5","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T17:07:21Z","timestamp":1568048841000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Larry C","family":"Lands","sequence":"first","affiliation":[{"name":"Montreal Children's Hospital; Department of Pediatrics; 2300 Tupper Street Montreal QC Canada H3H 1PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Stanojevic","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Department of Translational Medicine; 555 University Avenue Toronto ON Canada M5G 1X8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD001505.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0022-3476(05)82218-8","article-title":"Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects","volume":"118","author":"Konstan","year":"1991","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0004|cit2","unstructured":"Konstan MW Systemic anti-inflammatory treatment NSAID Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium 1995 L51"},{"issue":"13","key":"10.1002\/14651858.CD001505.pub5-BIB0002|cit3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0003|cit4","first-page":"S6.4","article-title":"Results of a four-year, randomized, placebo-controlled, double-blind trial of high-dose ibuprofen in CF patients with mild lung disease [abstract]","volume":"Suppl 10","author":"Konstan","year":"1994","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 24","key":"10.1002\/14651858.CD001505.pub5-BIB0005|cit5","first-page":"276","article-title":"High dose ibuprofen in CF children: the Trans-Canadian trial","volume":"34","author":"Lands","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD001505.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","article-title":"High-dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial","volume":"151","author":"Lands","year":"2007","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0008|cit7","first-page":"215","article-title":"A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia","volume":"Suppl 5","author":"Sordelli","year":"1990","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0007|cit8","first-page":"109","article-title":"A preliminary study of the effect of anti-inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection","volume":"7","author":"Sordelli","year":"1994","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001505.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jcf.2015.03.007","article-title":"Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis","volume":"14","author":"Chmiel","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0010|cit10","first-page":"228","article-title":"Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF","volume":"42 Suppl 30","author":"Chmiel","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD001505.pub5-BIB0011|cit11","first-page":"no pagination","article-title":"Acute sildenafil treatment improves exercise capacity in patients with cystic fibrosis","volume":"32","author":"Gonzalez","year":"2018","journal-title":"FASEB Journal. Experimental Biology Abstracts"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0012|cit12","first-page":"322","article-title":"CFTR effects of oral sildenafil in combination with lumacaftor\/ivacaftor in adults with CF","volume":"52 Suppl 47","author":"Hunt","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0013|cit13","unstructured":"Kovaleva LF Guembitskaia TE Gorbenko IA Aleshin YuN Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 155"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0014|cit14","unstructured":"Noritake D Hen J Dolan TF Effects of aspirin on pulmonary function in patients with cystic fibrosis Proceedings of the 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California 1981 144"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0015|cit15","first-page":"574","article-title":"The influence of aspirin on lung function in cystic fibrosis","volume":"46","author":"Noritake","year":"1982","journal-title":"Connecticut Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09629350410001688495","article-title":"Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease","volume":"13","author":"Pukhalsky","year":"2004","journal-title":"Mediator of Inflammation"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0017|cit17","first-page":"274","article-title":"Increase of the sputumneutrophil elastase activity in a paradoxical effect of the successful lung disease treatment in cystic fibrosis","volume":"32 (Suppl 22)","author":"Pukhalsky","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0018|cit18","unstructured":"Shmarina GV Pukhalsky AL Kashirskaja NJ Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-membrered ring macrolide antibiotic) European Respiratory Journal 2004 P3758"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0019|cit19","first-page":"299","article-title":"CTX- 4430 in a phase 1 clinical trial in cystic fibrosis patients","volume":"50 Suppl 41","author":"Ahuja","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0020|cit20","first-page":"S90","article-title":"Pharmacokinetic and pharmacodynamic profile of CTX -4430 in two phase 1 studies","volume":"14 Suppl 1","author":"Springman","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD001505.pub5-BIB0021|cit21","first-page":"S206","article-title":"A phase 1 clinical study of CTX-4430 in cystic fibrosis patients","volume":"64","author":"Springman","year":"2015","journal-title":"Inflammation Research"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0022|cit22","first-page":"S90","article-title":"A phase 1 clinical study of CTX-4430 in cystic fibrosis patients","volume":"14 Suppl 1","author":"Springman","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0023|cit23","first-page":"311","article-title":"A phase 1 clinical study of CTX-4430 in cystic fibrosis patients","volume":"49 Suppl 38","author":"Springman","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(18)30200-5","article-title":"A randomised controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe cystic fibrosis","volume":"17 Suppl 3","author":"Taylor-Cousar","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0025|cit25","first-page":"226","article-title":"Sildenafil improves cardiac performance, exercise intolerance and quality of life in moderate to severe cf lung disease","volume":"53 Suppl 2","author":"Tayor-Cousar","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD001505.pub5-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12890-017-0528-x","article-title":"Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial","volume":"17","author":"Vargas","year":"2017","journal-title":"BMC Pulmonary Medicine"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD001505.pub5-BIB0027|cit27","first-page":"293","article-title":"Preliminary safety profile of digitoxin to treat CF","volume":"49","author":"Callahan","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0028|cit28","first-page":"292","article-title":"Nasal microarray analysis in CF subjects taking digitoxin","volume":"50 Suppl 41","author":"Lee","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0029|cit29","first-page":"268","article-title":"Phase II study of digitoxin for CF","volume":"50 Suppl 41","author":"Zeitlin","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0031|cit30","unstructured":"Zeitlin PL Phase II study of digitoxin to treat cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT00782288"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0030|cit31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1513\/AnnalsATS.201608-649OC","article-title":"Digitoxin for airway inflammation in cystic fibrosis: preliminary assessment of safety, pharmacokinetics, and dose finding","volume":"14","author":"Zeitlin","year":"2017","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0032|cit32","first-page":"227","article-title":"A phase 2 trial (EMPIRE CF) of a novel anti-inflammatory molecule, acebilustat, in patients with cystic fibrosis","volume":"53 Suppl 2","author":"Elborn","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001505.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(18)30201-7","article-title":"Demographics of patients in a phase 2 trial of acebilustat in patients with cystic fibrosis (EMPIRE CF)","volume":"17","author":"Elborn","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cct.2018.07.014","article-title":"EMPIRE-CF: a phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics","volume":"72","author":"Elborn","year":"2018","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0035|cit35","unstructured":"NCT03265288 Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD) clinicaltrials.gov\/ct2\/show\/NCT03265288"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0036|cit36","unstructured":"NCT03451045 Trial to evaluate efficacy and safety of lenabasum in cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT03451045"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0037|cit37","unstructured":"Bertenshaw C Watson A Lewis S Smyth A A survey of acute renal failure in cystic fibrosis patients in the United Kingdom http:\/\/thorax.bmj.com\/"},{"issue":"1","key":"10.1002\/14651858.CD001505.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1385\/CRIAI:23:1:005","article-title":"The role of inflammation in the pathophysiology of CF lung disease","volume":"23","author":"Chmiel","year":"2002","journal-title":"Clinical Reviews in Allergy & Immunology"},{"issue":"12","key":"10.1002\/14651858.CD001505.pub5-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"European Journal of Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD001505.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"American Journal Respiratory and Critical Care Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD001505.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD001505.pub5-BIB0042|cit42","first-page":"186","article-title":"Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection","volume":"141","author":"Konstan","year":"1990","journal-title":"American Review of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3","article-title":"Current understanding of the inflammatory process in cystic fibrosis: onset and etiology","volume":"24","author":"Konstan","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001505.pub5-BIB0044|cit44","unstructured":"Konstan MW Personal Communication 1999"},{"issue":"3","key":"10.1002\/14651858.CD001505.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/jpet.103.052449","article-title":"Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects","volume":"306","author":"Konstan","year":"2003","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD001505.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001505.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1513\/AnnalsATS.201706-486OC","article-title":"Association of high-dose ibuprofen use, lung function decline and long-term survival in children with cystic fibrosis","volume":"15","author":"Konstan","year":"2018","journal-title":"Annals of the American Thoracic Society"},{"issue":"1","key":"10.1002\/14651858.CD001505.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJM199801013380115","article-title":"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis (letter)","volume":"338","author":"Kovesi","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1183\/09031936.00168007","article-title":"Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR","volume":"32","author":"Li","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD001505.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","article-title":"The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel","volume":"132","author":"Rosenstein","year":"1998","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD001505.pub5-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002203.pub2","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001505.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3476(84)80946-4","article-title":"Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study","volume":"104","author":"Wheeler","year":"1984","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001505","article-title":"Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis","author":"Dezateux","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001505.pub5-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001505","article-title":"Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis","author":"Lands","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001505.pub5-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001505.pub2","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","author":"Lands","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001505.pub5-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001505.pub3","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","author":"Lands","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001505.pub5-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001505.pub4","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","author":"Lands","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001505.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:34:16Z","timestamp":1697103256000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001505.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001505.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]}}}